| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SUPN | Common Stock | Options Exercise | $1.14M | +125K | +13.5% | $9.13 | 1.05M | Nov 7, 2024 | Direct | |
| transaction | SUPN | Common Stock | Sale | -$4.59M | -125K | -11.89% | $36.68 | 926K | Nov 7, 2024 | Direct | F1, F2 |
| holding | SUPN | Common Stock | 1.02M | Nov 7, 2024 | By the KBT Trust |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SUPN | Employee Stock Option (Right to Buy) | Options Exercise | $0 | -125K | -50% | $0.00 | 125K | Nov 7, 2024 | Common Stock | 125K | $9.13 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.27 to $37.24. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| F3 | The option vested in four equal installments beginning on March 3, 2016. |